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Human essential hypertension: 
no significant association 
of polygenic risk scores 
with antihypertensive drug 
responses
Heini Sánez tähtisalo1,2,8, Sanni Ruotsalainen3,8, Nina Mars3, Kimmo Porthan4,5, 
Lasse Oikarinen4, Juha Virolainen4, Frej Fyhrquist6, Samuli Ripatti3,7, Kimmo K. Kontula1,2 & 
Timo P. Hiltunen1,2*
Polygenic risk scores (PRSs) for essential hypertension, calculated from > 900 genomic loci, were 
recently found to explain a significant fraction of hypertension heritability and complications. To 
investigate whether variation of hypertension PRS also captures variation of antihypertensive drug 
responsiveness, we calculated two different PRSs for both systolic and diastolic blood pressure: one 
based on the top 793 independent hypertension-associated single nucleotide polymorphisms and 
another based on over 1 million genome-wide variants. Using our pharmacogenomic GENRES study 
comprising four different antihypertensive monotherapies (n ~ 200 for all drugs), we identified a weak, 
but (after Bonferroni correction) statistically nonsignificant association of higher genome-wide PRSs 
with weaker response to a diuretic. In addition, we noticed a correlation between high genome-wide 
PRS and electrocardiographic left ventricular hypertrophy. Finally, using data of the Finnish arm of 
the LIFE study (n = 346), we found that PRSs for systolic blood pressure were slightly higher in patients 
with drug-resistant hypertension than in those with drug-controlled hypertension (p = 0.03, not 
significant after Bonferroni correction). In conclusion, our results indicate that patients with elevated 
hypertension PRSs may be predisposed to difficult-to-control hypertension and complications thereof. 
No general association between a high PRS and less efficient drug responsiveness was noticed.
Elevated blood pressure (BP) has emerged as the leading risk factor for global disease burden, with a prevalence 
of 24% in males and 20% in females and totalling 1.1 billion affected adults  worldwide1. Hypertension has been 
estimated to account for approximately 9.4 million deaths  annually2. The insidious nature of hypertension is 
underscored by its high prevalence, its mostly asymptomatic nature, and slow progress in achievement of targets 
of treatment, calling for need of fundamental transformation in attempts of hypertension  control3.
There is much hope that better understanding of the underlying genetic mechanisms would result in more 
precise ways of screening, diagnostic classification and drug treatment of hypertension. Although major pro-
gress has been encountered in studies on pathophysiology and individualized treatment of monogenic forms 
of  hypertension4–6, the clinical usefulness of genomic techniques in patients with essential hypertension has 
remained limited. Genome-wide association studies (GWASs) have revealed up to 900 genetic loci associated 
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with elevated  BP7–10, but each locus mostly accounts for a very small degree (typically, 0.2 mmHg) of BP variation. 
Pharmacogenomic approaches have provided an alternative strategy to identify genetic markers of therapeutic 
responsiveness. Although large collaborative studies have reported promising genetic variants related to antihy-
pertensive drug  responses11–17, their ultimate clinical impact remains to be explored.
Calculation of polygenic risk scores (PRSs) from GWAS results has been shown to provide a promising 
technique for risk assessment of a number of complex diseases, including coronary artery disease, atrial fibril-
lation, type 2 diabetes, inflammatory bowel disease and breast  cancer18. The recent extension of BP-associated 
genomic markers showed that a PRS calculated across 901 independent genetic loci identified was associated 
with approximately 10 mmHg BP difference between the top and bottom quintiles of the PRS  distribution10. In 
addition, PRS was associated with increased risk of myocardial infarction and stroke, with odds ratios of about 
1.5 comparing top and bottom deciles of the PRS  distribution10.
In order to investigate whether variation of PRS based on all hypertension associated single-nucleotide poly-
morphisms (SNPs) also signals variation to antihypertensive drug responsiveness, we used our pharmacogenomic 
GENRES (Genetics of Drug Responsiveness in Essential Hypertension) Study as a primary  platform13,19. In 
GENRES, the antihypertensive effects of four different drug classes (a diuretic, a beta blocker, a calcium channel 
blocker and an angiotensin receptor antagonist) were studied in a placebo-controlled, rotational fashion, and 
genotyping was performed for the DNA samples, permitting calculation of PRSs for hypertension. We decided 
to replicate the corresponding data on beta blocker and angiotensin receptor antagonist responses using DNA 
samples and BP data from the Finnish arm of the LIFE (Losartan Intervention for Endpoint Reduction in 
Hypertension)  Study20. Accordingly, our data set provides a tool to investigate whether PRSs for BP also signifies 
antihypertensive drug responsiveness and whether any relation noted shows drug specificity.
Results
Patient characteristics.  Baseline characteristics for both GENRES and LIFE study subjects included in 
the analyses of BP responses are summarised in Table 1. Most noticeable differences between the GENRES and 
LIFE study populations were higher age, inclusion of females, and higher placebo systolic blood pressure (SBP) 
levels in the LIFE Study.
Polygenic risk scores in GENRES and LIFE.  We calculated two different PRSs for both SBP and diastolic 
blood pressure (DBP): one based on the top 793 independent BP-associated SNPs (Top_PRS) and another based 
on 1 million genome-wide variants (GW_PRS). All four PRSs, including  Top_PRSSBP,  Top_PRSDBP,  GW_PRSSBP 
and  GW_PRSDBP, were normally distributed in both the GENRES and the LIFE subjects (Fig. 1).
We validated our PRS estimates by calculation of their reciprocal correlations with placebo BP levels. In both 
patient cohorts,  Top_PRSSBP was correlated with  Top_PRSDBP (GENRES: r = 0.84; LIFE: r = 0.83), and  GW_PRSSBP 
was correlated with  GW_PRSDBP (GENRES: r = 0.76; LIFE: r = 0.76) (Supplementary Fig. S1 online). Furthermore, 
 Top_PRSSBP and  GW_PRSSBP were also correlated with each other (GENRES: r = 0.60; LIFE: r = 0.60), and likewise 
 Top_PRSDBP and  GW_PRSDBP were correlated (GENRES: r = 0.50; LIFE: r = 0.53) (Supplementary Fig. S2 online).
In GENRES there were positive correlations between all PRSs and placebo BP levels (r values 0.16–0.22, 
p values 0.001–0.02; Supplementary Table S1 online). In LIFE, these correlations were also positive and most 
reached statistical significance (Supplementary Table S1 online).
PRSs and left ventricular hypertrophy in GENRES.  As a further tool to validate our PRS data, we 
took advantage of the electrocardiographic (ECG) and echocardiographic studies of all GENRES patients. 
 GW_PRSSBP correlated significantly with ECG-estimated QRS area (p = 0.0004) and nonsignificantly with left 
ventricular mass index (LVMI) as estimated by echocardiography (p = 0.07), and with Sokolow-Lyon voltage 
(p = 0.04) and Cornell voltage product (p = 0.02) in ECG recordings (Table 2).  GW_PRSDBP was positively, but 
statistically nonsignificantly, correlated with QRS area (p = 0.05). Finally, in analyses of Top_PRSs and measures 
of LVH,  Top_PRSSBP correlated nonsignificantly with QRS area (p = 0.04). Collectively, our data suggest that 
elevated PRSs increase risk of left ventricular hypertrophy in hypertensive patients.
PRSs and antihypertensive drug responses.  In order to practically elucidate the possible associations 
between patient-specific PRSs and antihypertensive drug responses, we carried out two types of mathematical 
analyses. First, correlations between PRSs and covariate-adjusted BP responses in the two studies are summa-
rised in Table 3. No statistically significant associations, meeting the Bonferroni-corrected p value limit 0.003, 
were observed. The strongest observed correlations were those of antihypertensive responses to hydrochloro-
thiazide with genome-wide PRSs in GENRES, suggesting that higher PRSs were associated with weaker BP 
responses to this diuretic.
Second, in order to further characterize the drug responsiveness of the patients with the lowest and highest 
PRSs, an additional analysis was carried out in the first and fifth PRS quintiles. There were suggestive but sta-
tistically nonsignificant associations between the extreme GW_PRS quintiles and systolic (p = 0.11) or diastolic 
(p = 0.05) BP responses to hydrochlorothiazide, while no evidence was found for similar associations for the 
other three drugs (Fig. 2a). A partial replication study was conducted in the LIFE Study: bisoprolol responses in 
GENRES were compared to atenolol responses in LIFE, and losartan responses in both studies were compared; 
no significant correlations between the PRSs and drug responses were noticed (Fig. 2b).
Due to the observed suggestive associations of genome-wide PRSs with BP responses to hydrochlorothiazide 
(Table 3), their predictive performance for good BP response was further evaluated using receiver operating 
characteristic (ROC) analysis. The threshold for good response to hydrochlorothiazide was set at covariate-
adjusted BP change better than − 0.5 s.d. (corresponding to − 8.0/− 3.8 mmHg SBP/DBP responses). The area 
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under ROC curve for SBP response, predicted by  GW_PRSSBP, was 0.64 (p = 0.0009; the highest Youden index 
0.25 with a sensitivity of 0.61 and a specificity of 0.63), and the corresponding results for DBP response, predicted 
by  GW_PRSDBP, was 0.63 (p = 0.002; the highest Youden index 0.24 with a sensitivity of 0.48 and a specificity of 
0.77) (Supplementary Fig. S3 online). Regardless of the p values, the area under curve and the highest Youden 
index values are low and indicate poor predictive value of the genome-wide PRSs for practical prediction of BP 
responses to hydrochlorothiazide.
PRSs and drug treatment-resistant hypertension.  In order to obtain a surrogate index of drug sensi-
tivity and drug resistance in the GENRES Study, we calculated a mean standardized response rate using data for 
all four antihypertensive drugs used in the study (see “Methods” section). There was only a weak and statistically 
nonsignificant correlation of the genome-wide risk scores with the mean integrated BP responses in GENRES: 
 GW_PRSSBP vs SBP response (r = 0.11, p = 0.12),  GW_PRSDBP versus DBP response (r = 0.10, p = 0.15). On the 
same line, when the subjects were grouped into quintiles on the basis of their PRSs, no differences between the 
extreme PRS quintiles emerged (Fig. 3).
We next explored whether there is evidence for association of high PRS with resistance to antihypertensive 
therapy in the LIFE Study. In LIFE, 177 subjects were judged to have controlled hypertension and 169 sub-
jects to have treatment-resistant hypertension at 2 years of the study. Their baseline characteristics are summa-
rised in Supplementary Table S2 online.  GW_PRSSBP was found to be slightly, but (after Bonferroni correction) 
Table 1.  Characteristics of the study subjects included in the analyses of blood pressure responses. Values are 
presented as mean ± s.d., unless otherwise stated. Δ change, DBP diastolic blood pressure, GW genome-wide, 
PRS polygenic risk score, SBP systolic blood pressure. a Depending on the drug (see “Methods” section). b Blood 
pressure responses are from 24-h ambulatory recordings for GENRES and from office measurements for LIFE. 
c Bisoprolol in GENRES, atenolol in LIFE.
Parameters GENRES
LIFE
Atenolol Losartan
n 203–207a 201 200
Age (years) 50.6 ± 6.4 64.0 ± 6.5 63.9 ± 5.9
Men (%) 100 52 48
Body mass index (kg m−2) 26.7 ± 2.7 27.2 ± 3.6 27.7 ± 3.4
Current smoker (%) 16 10 12
Creatinine (µmol/l) 86 ± 13 80 ± 13 82 ± 17
Potassium (mmol/l) 4.4 ± 0.3 4.3 ± 0.3 4.2 ± 0.3
Urate (µmol/l) 372 ± 64 327 ± 66 336 ± 70
Glucose (mmol/l) 5.4 ± 0.6 5.5 ± 1.1 5.7 ± 1.5
Total cholesterol (mmol/l) 5.6 ± 0.9 6.1 ± 0.9 5.9 ± 1.0
Blood pressure levels on placebo
Ambulatory SBP (mmHg) 135 ± 10 NA NA
Ambulatory DBP (mmHg) 93 ± 6 NA NA
Office SBP (mmHg) 152 ± 13 166 ± 13 166 ± 12
Office DBP (mmHg) 100 ± 7 98 ± 6 97 ± 6
Blood pressure responsesb
 Amlodipine
  ΔSBP (mmHg) − 7.4 ± 7.2 NA NA
  ΔDBP (mmHg) − 4.9 ± 4.0 NA NA
 Beta  blockerc
  ΔSBP (mmHg) − 11.1 ± 6.2 − 21.4 ± 12.8 NA
  ΔDBP (mmHg) − 8.3 ± 4.2 − 12.8 ± 6.6 NA
 Hydrochlorothiazide
  ΔSBP (mmHg) − 4.8 ± 6.3 NA NA
  ΔDBP (mmHg) − 1.7 ± 4.1 NA NA
 Losartan
  ΔSBP (mmHg) − 9.1 ± 6.7 NA − 20.8 ± 12.2
  ΔDBP (mmHg) − 6.1 ± 4.7 NA − 10.9 ± 7.3
Genetic risk scores
Top_PRSSBP 2.10 ± 1.87 1.87 ± 1.86 2.02 ± 1.93
Top_PRSDBP 0.63 ± 1.04 0.36 ± 1.13 0.41 ± 1.13
GW_PRSSBP 0.53 ± 0.22 0.45 ± 0.24 0.46 ± 0.23
GW_PRSDBP 0.57 ± 0.23 0.45 ± 0.24 0.46 ± 0.24
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Figure 1.  Distributions of Top_PRSs and GW_PRSs in GENRES (a–d) and LIFE (e–h). All PRSs are unitless 
and expressed as relative values.
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statistically nonsignificantly higher in the group of treatment-resistant hypertension than in controlled hyper-
tension (p = 0.03 in t test and p = 0.02 in covariate-adjusted linear regression), while no difference was noted in 
the corresponding analysis of  GW_PRSDBP (Fig. 4). Similar, statistically nonsignificant results were revealed for 
 Top_PRSSBP (p = 0.05 in t test and p = 0.05 in covariate-adjusted linear regression) and no difference was observed 
in comparison of the  Top_PRSDBP of controlled and treatment-resistant hypertensive patients of the LIFE study 
(Supplementary Table S2 online).
PRSs and cardiovascular endpoints in the LIFE Study.  A total of 70 subjects in the LIFE Study expe-
rienced a primary composite endpoint (cardiovascular death, stroke, myocardial infarction), while 977 subjects 
did not. Their baseline characteristics and the results from Cox regression analysis of the association between the 
PRSs and the occurrence of the primary composite endpoint are summarised in Supplementary Table S3 online. 
In endpoint analyses, only a nonsignificant association between  GW_PRSSBP and occurrence of the endpoint was 
seen (p = 0.08 in Cox regression analysis, Supplementary Table S3 online).
Table 2.  Correlation of GW_PRSs (a) and Top_PRSs (b) with measures of left ventricular hypertrophy (LVH) 
during placebo periods in GENRES. Linear regression with covariates listed in “Methods” section was used. 
Bonferroni-corrected p values < 0.0018 were considered statistically significant.
LVH measures n
GW_PRSSBP GW_PRSDBP
Std beta p Std beta p
a
Left ventricular mass index 221 0.12 0.07 − 0.01 0.91
Sokolow-Lyon voltage 227 0.13 0.04 0.08 0.21
Cornell voltage product 226 0.16 0.02 0.01 0.93
QRS area sum 227 0.24 0.0004 0.13 0.051
LVH measures n
Top_PRSSBP Top_PRSDBP
Std beta p Std beta p
b
Left ventricular mass index 221 0.03 0.63 − 0.01 0.89
Sokolow-Lyon voltage 227 0.02 0.71 0.04 0.57
Cornell voltage product 226 0.13 0.06 0.08 0.23
QRS area sum 227 0.14 0.04 0.11 0.10
Table 3.  Correlations between PRSs and covariate-adjusted blood pressure responses in GENRES (a) 
and LIFE (b). PRSs for SBP were correlated with SBP responses and PRSs for DBP were correlated with 
DBP responses. Pearson correlation test was used for these analyses; a positive r-value indicates a weaker 
BP response with increasing PRS value. *r values 0.16/0.18 correspond to 0.92/0.69 mmHg changes in BP 
responses per 1 SD changes in  GW_PRSSBP/GW_PRSDBP.
Blood pressure responses
Amlodipine Bisoprolol Hydrochlorothiazide Losartan
n = 205 n = 207 n = 206 n = 203
r p r p r p r p
a. GENRES
Top_PRSSBP 0.05 0.48 − 0.10 0.17 0.05 0.51 0.02 0.77
Top_PRSDBP − 0.01 0.84 − 0.02 0.83 0.09 0.20 − 0.01 0.88
GW_PRSSBP 0.05 0.44 − 0.03 0.63 0.16* 0.03 0.06 0.38
GW_PRSDBP 0.08 0.24 − 0.04 0.59 0.18* 0.01 0.06 0.43
Blood pressure responses
Atenolol Losartan
n = 201 n = 200
r p r p
b. LIFE
Top_PRSSBP 0.006 0.89 0.01 0.77
Top_PRSDBP 0.007 0.89 − 0.06 0.20
GW_PRSSBP − 0.03 0.48 0.03 0.57
GW_PRSDBP 0.03 0.48 − 0.03 0.53
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Figure 2.  Covariate-adjusted blood pressure responses by the lowest/highest genome-wide PRS quintiles 
in GENRES (a) and LIFE (b). Box-and-whisker plots are presented. p values are from Student’s t test when 
comparing the lowest and the highest PRS quintiles. HCTZ hydrochlorothiazide.
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Discussion
We investigated whether variation of PRSs based on all presently known hypertension-associated SNPs signals 
variation on BP responses to four commonly used classes of antihypertensive drugs. We found some, but consid-
ering the multiple comparisons, statistically nonsignificant evidence for higher PRSs associating with less efficient 
BP response to a thiazide diuretic, but no support for similar associations between PRSs and effects of three other 
classes of antihypertensive drugs. Furthermore, we observed a significant relation between high  GW_PRSSBP 
and an index of LVH, as well as a suggestive but statistically nonsignificant association between high PRS values 
and occurrence of drug-resistant hypertension. The present study appears to be the first on genomic risk scores 
in prediction of antihypertensive drug effects, as previous studies have been concentrated on hypertension per 
 se10,18,21, or on complications of  hypertension22,23.
In order to identify tools for optimal use of polygenic risk scores for future drug response studies of human 
hypertension, we used four different genomic risk scores for our analyses: two based on 793 SNPs associated with 
systolic or diastolic BP, and two genome-wide risk scores taking into account genomic variation at over a mil-
lion of loci. The conventional way of calculating PRSs has been to calculate them from a subset of independent, 
associated genetic markers based on GWAS summary statistics (applying LD pruning and p value threshold), 
corresponding to the Top_PRSs of the current study. This approach has advantages in terms of computational 
simplicity and has been used to predict genetic liability across a broad phenotypic  spectrum24. In the current 
study, we used a single p value threshold of < 0.05 but it is also possible to apply more relaxed p value thresholds 
for the calculation of the Top_PRSs, which might improve their performance. However, finding the optimal 
threshold for genome-wide prediction would need a large training set independent of the original GWAS and 
was outside of the scope of this study. Recently, Bayesian methods to generate a SNP set for PRS by calculating 
Figure 3.  Mean covariate-adjusted SBP (a) and DBP (b) change on the four study drugs in the lowest/highest 
GW_PRS quintiles in GENRES. The BP changes are shown as s.d. units; box-and-whisker plots are presented. p 
values are from Student’s t test when comparing the lowest and the highest PRS quintiles.
Figure 4.  Comparison of genome-wide polygenic risk scores for SBP (a) and DBP (b) between subjects with 
treatment-resistant hypertension (RHTN) and controlled hypertension (HTN) in LIFE at 2 years of the study. 
Box-and-whisker plots are presented. p values are from Student’s t test when comparing subjects with controlled 
and treatment-resistant hypertension. Both PRSs are unitless and expressed as relative values.
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the posterior effect sizes from GWAS summary statistics conditioned by an LD information from a reference 
panel have been increasingly  used24,25. The main advantage from this method compared to conventional LD 
pruning and p value threshold-based method is that it includes SNPs across a broad range of p values and may 
thus account for possible hidden signals retrieved by omitting  pruning25. This prompted us to use also the 
GW_PRSs in our calculations.
Furthermore, we took advantage of use of two meticulously phenotyped samples of hypertensive patients, 
originating from the Finnish population. We obtained qualification for the use of these cohorts by showing that 
higher PRSs were correlated with higher baseline (placebo) BP levels in both GENRES and LIFE (Supplementary 
Table S1 online).
When analysing associations between PRSs and antihypertensive responses of four drug classes, it was intrigu-
ing to notice that any indication for possible relation between elevated GW_PRS and weaker BP response was 
observed only for a diuretic (Table 3 and Fig. 2). Although the extent of this relation did not reach statistical 
significance after the conservative Bonferroni correction on this occasion, we take our finding as an interesting 
hint toward further investigations. Accordingly, whether this preliminary finding indicates that the genomic 
loci relevant to PRS calculation reflect mechanisms that are especially associated with volume expansion awaits 
for additional studies. Regarding the Top_PRSs, they did not display any association with BP responses to the 
diuretic. This is probably related to their only moderate correlation with the GW-PRSs (r values ~ 0.6 and  r2 
values ~ 0.36; see also Supplementary Fig. S2 online) and may be a sign of BP-associated loci that fall below 
genome-wide significance.
Evidence for the assumption that a high hypertension PRS is an indication for more intensive drug therapy 
comes from two other lines of the present study. First, we observed certain correlations between PRSs and meas-
ures of LVH. Echocardiographic evidence of LVH was available from the GENRES group, indicating a trend 
toward correlation between LVMI and the  GW_PRSSBP (Table 2). In addition, three electrocardiographic LVH 
indices showed significant or suggestive correlations with the patients’ PRSs (Table 2).
Second, some evidence favouring use of PRS values for predictive purposes comes from analyses of resistant 
patients. Resistant hypertension is often defined as the lack of attainment of a target BP level despite the use of 
at least three different antihypertensive drugs, of which at least one should include a  diuretic26. Resistant hyper-
tension is a distinctly ominous feature, associating with increased risk of complications, including myocardial 
infarction, congestive heart failure, stroke and kidney failure. We were able to directly analyse the possible relation 
of drug-resistant hypertension to PRS values in the LIFE cohort. Indeed,  GW_PRSSBP was nominally associated 
(p = 0.03) with drug-resistant hypertension in LIFE (Fig. 4). Our end-point analysis data in LIFE (Supplementary 
Table S3 online) did not reveal statistically significant associations, possibly due to the facts that the number of 
endpoints among the Finnish LIFE patients was limited and because these patients were already selected accord-
ing to their elevated risk. However, our data are not in disagreement with the end-point data of Evangelou et al.10, 
originally providing the platform of hypertension PRS estimation. It is also of note that in GENRES we noticed 
a trend toward less efficient BP lowering in patients with high PRSs when we used a composite response index 
taking into account all individual responses to the four drug classes (a diuretic, beta-blocker, calcium channel 
antagonist, angiotensin receptor antagonist) used. These data on drug resistance justify careful replication stud-
ies coming from other pharmacogenomic studies of human hypertension. In summary, we have generated data 
supporting the assumption that hypertension PRSs may have predictive role in identification of patients requiring 
more intensive drug treatment to reach BP targets and to avoid complications of hypertension. However, since 
most of these findings did not reach statistical significance when performance of multiple comparisons was 
considered, these aspects require further studies in other populations.
Our study has some important limitations. Although in its design the GENRES Study is an almost ideal for 
pharmacogenomic studies, its sample size is limited and it consists of males only; in addition, there is no follow-
up data for the GENRES patients. The Top_PRSs were calculated with a single and strict p value threshold of 
< 0.05 and yielded associations less significant than those obtained with the GW_PRSs. It is, however, possible 
that Top_PRSs based on more relaxed p value thresholds could perform better. Due to the design of the LIFE 
Study, data on thiazide and calcium channel antagonist could not be replicated in it. In addition, only subjects 
on monotherapy at 2 months’ visit were included in the BP response analyses of the LIFE Study, which excludes 
many nonresponders and reduces the power of the analyses. It should also be emphasized that 24-h ambulatory 
BP data were used in GENRES while office BP measurements took place in LIFE.
In conclusion, our data indicate that patients with elevated hypertension PRSs are predisposed to difficult-to-
control hypertension and complications thereof. Whether a high PRS indeed signals less efficient responsiveness 
to thiazide diuretics awaits additional investigations in other, and possibly larger, clinical studies.
Methods
Patients.  The general design of the GENRES Study has been described  previously19. In brief, it is a rand-
omized, double-blind, placebo-controlled, rotational study using four different antihypertensive monotherapies. 
The study subjects were 35–60 year old Finnish men with moderate hypertension. The study protocol included 
a 4-week initial wash-out placebo period, followed by 4-week drug monotherapy periods (hydrochlorothiazide 
25 mg, bisoprolol 5 mg, losartan 50 mg, amlodipine 5 mg), separated by 4-week placebo periods (Supplementary 
Fig. S4 online). Measurement of office BP and 24-h ambulatory BP recording were carried out after each drug 
and placebo period. For the present study, we selected the patients with imputed genotype data and ambulatory 
BP response data for at least one drug (205 for amlodipine, 207 for bisoprolol, 206 for hydrochlorothiazide, and 
203 for losartan). The clinical part of the study was carried out in accordance with the Declaration of Helsinki 
and Guidelines for Good Clinical Practice (1996). The study was approved by the Ethics Committee of Helsinki 
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University Hospital and the National Agency for Medicines of Finland. All screened subjects gave a signed 
informed consent prior to study activities.
The LIFE study is an international, randomized, double-blind study originally aimed at evaluating the long-
term treatment effects of losartan compared with atenolol in 9,193 hypertensive patients with signs of  LVH27. 
Patients were randomly assigned to treatment with losartan (50 mg daily) or atenolol (50 mg daily) after a 
2-week wash-out placebo period. Hydrochlorothiazide 12.5 mg daily was then added to the treatment if target 
BP (< 140/90 mmHg) was not achieved. Later treatment escalations included increase of the study drug dose 
to 100 mg, increase of hydrochlorothiazide dose to 25 mg and addition of other antihypertensive drugs (Sup-
plementary Fig. S4 online). A pharmacogenetic substudy was done in Scandinavia, including 1,146 Finnish 
patients whose DNA samples were available for  GWAS20. Of this group, a total of 401 patients on monotherapy 
at 2 months’ visit (losartan, n = 200; atenolol, n = 201) were selected for analysis of BP responses in the current 
study. The numbers of subjects included for analysis of treatment-resistant hypertension and for cardiovascular 
endpoints were 346 and 1,047, respectively (see below). The main treatment protocol of the LIFE study and the 
protocol of the genetics substudy were approved by local ethical committees and done in accordance with the 
Declaration of Helsinki. All participants gave a written informed consent before study.
Electrocardiographic and echocardiographic studies in the GENRES Study.  A digital standard 
resting 12-lead ECG was recorded at the end of all eight GENRES study periods (Marquette MAC 5,000 electro-
cardiograph, GE Marquette Medical Systems, Milwaukee, WI). QT Guard 1.3 software (GE Marquette Medical 
Systems) produced automatically digital median QRS-T complexes for all 12 leads. Electrocardiographic evi-
dence for LVH was explored using three different methods: calculation of the QRS area (mean integral value of 
the QRS complexes of all leads), estimation of Sokolow-Lyon voltage (defined as  SV1 + RV5 or  RV6, whichever was 
greater) or calculation of Cornell voltage product, defined as  (SV3 + RaVL) × QRS duration.
Transthoracic echocardiography was performed at the end of the first placebo period in the GENRES 
Study. All echocardiographic measurements were averaged from five cardiac cycles, and were available for 
221 (96.9%) subjects. Left ventricular mass in grams was calculated with an anatomically validated formula: 
0.8 × [1.04 × ((interventricular septal thickness + left ventricular end-diastolic diameter + posterior wall thick-
ness)3  – left ventricular end-diastolic  diameter3)] + 0.6. LVMI was indexed to body surface area.
Treatment-resistant hypertension in the LIFE Study.  Treatment-resistant hypertension status was 
defined at the 2 years’ visit, which allowed enough time for BP medication titration and reduced the number of 
exclusions (due to experiencing study outcomes or censoring). Treatment-resistant hypertension was defined as 
SBP ≥ 140 mmHg or DBP ≥ 90 mmHg and the use of at least three different antihypertensive drugs. Controlled 
hypertension was defined as SBP < 140 mmHg and DBP < 90 mmHg with a maximum of three drugs.
Before exclusions, 387 subjects could be classified to treatment-resistant or controlled hypertension. After 
exclusions [loss from follow-up (n = 3), morbid obesity (body mass index > 40 kg/m2, n = 6), macroalbuminuria 
(> 300 mg/l, n = 3), unsuccessful genotyping (n = 26), and occurrence of a primary composite endpoint before 
year 2 (stroke, n = 3)], 169 subjects with treatment-resistant hypertension, and 177 with controlled hypertension 
remained in the analysis.
Cardiovascular endpoints in the LIFE Study.  For the analysis of cardiovascular endpoints, the primary 
composite endpoint (cardiovascular mortality, stroke, and myocardial infarction) of the LIFE Study was  used27.
After exclusions [morbid obesity (body mass index > 40 kg/m2, n = 14), macroalbuminuria (> 300 mg/l, n = 12), 
first degree relativeness (n = 6), and unsuccessful genotyping (n = 67)], the total amount of subjects included in 
the analyses was 1,047; the primary composite endpoint occurred in 70 (6.9%) of them.
Genotyping and imputation.  The genotyping methods and quality control steps for GENRES and LIFE 
have been described in detail  before13,20. The DNA samples were genotyped at the Institute for Molecular Medi-
cine Finland (FIMM, Helsinki, Finland) using the Illumina HumanOmniExpress BeadChip (Illumina, San 
Diego, CA, USA). Genotype data and reference genome builds were lifted over to build version 38 (GRCh38/
hg38) following the protocol described (dx.doi.org/10.17504/protocols.io.nqtddwn). In sample-wise quality 
control, individuals with high genotype missingness (> 5%) and excess heterozygosity (± 4SD) were removed; 
there were no subjects of non-Finnish ancestry. In variant-wise quality control prior imputation variants with 
high missingness (> 2%), low HWE p value (< 1 × 10–6) and minor allele count < 3 were removed. Phasing and 
imputation of the genotypes were done utilizing a Finnish population-specific reference panel (SISu v3) of 3,775 
high-coverage whole-genome sequences as described (dx.doi.org/10.17504/protocols.io.nmndc5e).
Calculation of individual polygenic risk scores.  We calculated two different patient-specific PRSs for 
both SBP and DBP: one based on the top 793 independent (LD-pruned) hypertension-associated SNPs (Top_
PRS) listed in Supplementary Table S4 online, and another genome-wide PRS (GW_PRS). Information on the 
presently known genomic loci associated with hypertension per se was obtained from the study of Evangelou 
et al.10.
For calculation of Top_PRS for each subject, we selected only those 793 SNPs that were associated (p < 0.05) 
with either SBP or DBP, omitting SNPs that were associated with only pulse  pressure10. The allelic weights were 
directly acquired from the data of Evangelou et al.10 by request.
In order to calculate the GW_PRSs for each individual we used the PRS-CS  method24, which is a Bayesian 
method to infer posterior effect sizes for variants using summary statistics from GWAS and an external linkage 
disequilibrium (LD) reference panel.
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In calculation of GW_PRSs, we used 1000G  EUR28 as LD reference panel and limited our calculation for 
variants from Hapmap3 phase  329 totalling 1,085,815 for SBP and 1,085,696 variants for DBP.
Statistics.  The statistical analyses were run using SPSS version 22.0 (IBM SPSS Statistics, Armonk, NY). All 
analysed BP values in the GENRES study were based on ambulatory 24-h recordings. The mean BP level of all 
(up to four) placebo periods was used as the baseline level. BP responses to antihypertensive drugs were calcu-
lated as BP after 4 weeks’ drug treatment minus baseline BP. In the LIFE study, BP levels were derived from office 
measurements. BP responses were calculated as BP after 2 months’ drug treatment minus BP after the 2-week 
wash-out placebo period. Normality of data was assessed using skewness of the distributions.
The associations of PRSs with BP responses were analysed using BP response residuals generated with step-
wise linear regression. Covariates used for BP residual calculations in GENRES were chosen from the following 
parameters in a drug-specific fashion using stepwise regression (p < 0.10 as the inclusion criterion): the corre-
sponding mean BP level on all placebo periods, age, earlier use of antihypertensive medication, current smoking, 
body mass index, and daily urinary sodium excretion and serum creatinine after the first placebo  period13. The 
distributions of the BP response residuals did not deviate significantly from normal distribution, as judged by 
evaluation of skewness and Kolmogorov–Smirnov test (smallest p value was 0.08). The distributions of the BP 
response residuals are shown in Supplementary Fig S5 online. In LIFE, the following covariates were used in 
addition to the corresponding BP level on placebo for all BP responses: sex, age and body mass index. Covariates 
included are listed in a cohort- and drug-specific way in Supplementary Tables S5 and S6 online.
Pearson correlation test was used to analyse the association between PRSs and BP response residuals. To 
further describe the associations between PRSs and BP responses, both study populations were divided into PRS 
quintiles. The lowest and the highest quintiles were then compared with Student’s t test.
To analyse the association of PRSs with the mean BP response to the four drugs in the GENRES study, each 
ambulatory BP response to the study drug was covariate-adjusted and standardized (mean = 0, SD = 1) after 
which the means of the standardized SBP and DBP responses to the four study drugs were calculated. The mean 
standardized responses were then analysed in a way similar to the monotherapy BP responses.
The predictive performance of PRSs for good BP response was evaluated using ROC analysis with SPSS 
program (version 22.0, IBM SPSS Statistics, Armonk, NY).
The associations between PRSs and LVH measures were analysed with linear regression. In addition to the 
analysed PRS, covariates were included in the model using stepwise regression (p < 0.10 as an inclusion condi-
tion). The covariates tested were age, body mass index, height and body surface area. Of these covariates, age 
(but none of the body size-related parameters) was included in analyses of LVMI (p values ranging from 0.007 
to 0.008 with the various PRSs). In the analyses of the ECG measures of LVH, body mass index was the only 
additional covariate that was included in the models: its p values ranged from 9 × 10–6 to 0.0001 for Sokolow-Lyon 
voltage, from 0.01 to 0.07 for Cornell voltage product, and from 0.003 to 0.002 for QRS area. Normalized values 
were used for QRS area because of its non-normal distribution. Electrocardiographic recordings were available 
from up to four placebo periods and the means of them were used in the analyses.
In LIFE, the PRSs between subjects with treatment-resistant hypertension and controlled hypertension were 
compared using Student’s t test. Linear regression analysis (SPSS General Linear Model) was run to verify the 
results using sex, current smoking, treatment arm, estimated glomerular filtration rate, and body mass index 
as covariates.
Cox regression was used to analyse the association of PRSs with the occurrence of the primary composite 
endpoint using the following covariates: sex, current smoking, diabetes, earlier cardiovascular disease, treatment 
arm, and age.
The drug response study included multiple comparisons due to several primary target variables (systolic and 
diastolic BP responses to four drug treatments, and two separate PRSs for each response). For these analyses, 
the Bonferroni-corrected p value limit for statistical significance was set at 0.003 (= 0.05/16). This approach can 
be considered very conservative, since the systolic and diastolic BP responses to each drug correlate highly (r 
values > 0.8) as do the top-SNP and genome-wide PRSs (r values ~ 0.6). For the analysis of the secondary target 
variables, the Bonferroni-corrected p value was calculated considering the following analyses: four different LVH 
measures and four PRSs, two mean BP responses (systolic and diastolic) to the four study drugs in GENRES and 
two PRSs for both responses, treatment-resistant hypertension in LIFE and four PRSs, cardiovascular endpoints 
in LIFE and four PRSs. This gives a Bonferroni-corrected p value limit of 0.0018 (0.05/(4 × 4 + 2 × 2 + 4 + 4)) for 
statistical significance.
To assess the statistical power of our primary correlation analysis, we calculated the power for three different 
correlation coefficients: 0.1, 0.18 and 0.4. We used n = 207, corresponding to the GENRES data set sample size, 
and the Bonferroni-corrected p value threshold of 0.003. The corresponding powers were: 0.06, 0.35 and 0.999.
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